Show simple item record

dc.contributor.authorMelendez-Torres, G. J.
dc.contributor.authorAuguste, Peter
dc.contributor.authorArmoiry, Xavier
dc.contributor.authorMaheswaran, Hendramoorthy
dc.contributor.authorCourt, Rachel
dc.contributor.authorMadan, Jason
dc.contributor.authorKan, Alan
dc.contributor.authorLin, Stephanie
dc.contributor.authorCounsell, Carl
dc.contributor.authorPatterson, Jacoby
dc.contributor.authorRodrigues, Jeremy
dc.contributor.authorCiccarelli, Olga
dc.contributor.authorFraser, Hannah
dc.contributor.authorClarke, Aileen
dc.date.accessioned2017-09-28T09:00:19Z
dc.date.available2017-09-28T09:00:19Z
dc.date.issued2017-09-01
dc.identifier.citationMelendez-Torres , G J , Auguste , P , Armoiry , X , Maheswaran , H , Court , R , Madan , J , Kan , A , Lin , S , Counsell , C , Patterson , J , Rodrigues , J , Ciccarelli , O , Fraser , H & Clarke , A 2017 , ' Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation ' , Health Technology Assessment , vol. 21 , no. 52 , pp. 1-352 . https://doi.org/10.3310/hta21520en
dc.identifier.issn1366-5278
dc.identifier.otherPURE: 108944767
dc.identifier.otherPURE UUID: 6b8ae18f-7010-42d1-87c3-e125c6387795
dc.identifier.otherScopus: 85030177121
dc.identifier.urihttp://hdl.handle.net/2164/9366
dc.descriptionThe authors gratefully acknowledge the assistance of Ms Karoline Munro and Dr Martin Connock. The authors also acknowledge the work and assistance of Charles Dobson and the RSS Steering Group.en
dc.format.extent352
dc.language.isoeng
dc.relation.ispartofHealth Technology Assessmenten
dc.rights© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Permission to reproduce material from a published report is covered by the UK government’s non-commercial licence for public sector information.en
dc.subjectR Medicine (General)en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccR1en
dc.titleClinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluationen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Chronic Disease Research Groupen
dc.contributor.institutionUniversity of Aberdeen.Data Safe Havenen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.3310/hta21520


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record